Information for "Pembrolizumab A good Immunotherapeutic Adviser Causing Endocrinopathies"
Basic information
| Display title | Pembrolizumab A good Immunotherapeutic Adviser Causing Endocrinopathies |
| Default sort key | Pembrolizumab A good Immunotherapeutic Adviser Causing Endocrinopathies |
| Page length (in bytes) | 3,853 |
| Namespace ID | 0 |
| Page ID | 169677 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Disallowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | 23.231.38.245 (talk) |
| Date of page creation | 12:01, 16 December 2023 |
| Latest editor | 23.231.38.245 (talk) |
| Date of latest edit | 12:01, 16 December 2023 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
